Reference
Browse every peptide we cover — search and filter by category, status and class. Mechanism, half-life, dosing reference and links to in-depth guides.
Dose ranges and half-life values are reference points from trial protocols and approved labels — not dosing recommendations.
Start with a category hub for comparison tables, evidence scores and FAQ targeting the main research use cases.
Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.
Healing PeptidesCompare healing peptides such as BPC-157 and TB-500 by evidence quality, mechanism, research status and practical limitations.
Growth Hormone PeptidesCompare growth hormone peptides including ipamorelin, CJC-1295 and tesamorelin by GH-axis mechanism, approval status, half-life and evidence score.
Cognitive PeptidesCompare cognitive peptides such as Selank and Semax by mechanism, route, regional clinical history, evidence score and research limitations.
Longevity PeptidesCompare longevity peptides by evidence quality, mechanism and practical research limits, starting with GHK-Cu and copper peptide data.
Body Protection Compound-157
Derived from human gastric juice. Animal models suggest effects on angiogenesis, tendon healing and GI repair; human clinical data is very limited.
AM833
Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).
DAC:GRF
Long-acting growth-hormone-releasing hormone analog. The DAC variant binds serum albumin to extend half-life and sustain GH/IGF-1 elevation.
Copper tripeptide-1
Naturally occurring tripeptide bound to copper. Studied for wound healing, skin remodeling and gene-expression effects related to tissue repair.
NNC 26-0161
Selectively stimulates pituitary growth hormone release without significant cortisol or prolactin elevation seen with older GHRPs.
Victoza, Saxenda
Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.
LY3437943
Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.
TP-7
Russian-developed analog of tuftsin marketed (in Russia) as an anxiolytic. Mechanism involves modulation of GABA and stress-response pathways.
Ozempic, Wegovy, Rybelsus
Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.
ACTH(4-10) analog
Heptapeptide derived from ACTH(4-10). Russian neuropeptide studied for nootropic and neuroprotective effects, partly via BDNF upregulation.
BI 456906
Co-activates GLP-1 and glucagon receptors; in Phase 2 produced substantial weight reduction and improvement in MASH endpoints.
Thymosin Beta-4 fragment
Synthetic fragment of thymosin β4 studied in animal models for cell migration, angiogenesis and tissue repair. No approved human indication.
Egrifta
Stabilized GHRH analog. Approved for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.
LY3298176, Mounjaro, Zepbound
Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.
Research & educational purposes only
The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.